• H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and price target, seeing an upside potential of over 100%.

  • A strategic portfolio of targeted therapies in oncology "gives Tempest an edge," analyst Joseph Pantginis tells investors in a research note.

  • According to him, Tempest sets itself apart from other companies in the immuno-oncology space by shifting its focus to innovative targets and mechanisms.

  • Recently, Tempest began trading on the NASDAQ through a reverse merger with Millendo Therapeutics.

  • Sam Whiting, chief medical officer, will participate in a webcast panel titled "Developing Therapies for the Next Immuno-Oncology Targets" at the William Blair 2021 Biotech Focus Conference tomorrow.

  • Price Action: TPST shares are up 5.42% at $25.50 during the premarket session on the last check Tuesday.

Latest Ratings for TPST

Jul 2021

HC Wainwright & Co.

Initiates Coverage On


Jul 2021

Piper Sandler

Initiates Coverage On


View More Analyst Ratings for TPST
View the Latest Analyst Ratings

See more from Benzinga

  • Click here for options trades from Benzinga

  • Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab

  • Hepion Pharma's NASH Candidate Aces Mid-Stage Study

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888